| Management target | Revenue 15.0% FY30 |
|---|
| Revenue growth | 25% YoY growth in Q1-FY27. |
|---|---|
| Margins | EBITDA margin expanded to 21.83% in Q1-FY27. |
| Demand visibility | High due to rising cancer burden and IVF needs. |
| Management confidence | High; citing 'Vision 2030' strategic transformation. |
Growth
Revenue grew from INR 1,002 Mn (Q1-FY26) to INR 1,255 Mn; PAT rose 41% YoY to INR 165 Mn.
Outlook
Vision 2030 targets 51% revenue from domestic branded formulations; 15% CAGR guided for Indian IVF market.
Risks
Rising input costs due to geopolitical environment; heavy reliance on oncology segment before diversification.
Last quarter's promises, checked
Delivered
- Guided 20-25% Revenue Growth → delivered 25% (= BEAT)
- Guided EBITDA margin 21.1% to ~22% → delivered 21.83% (= BEAT)
- Guided start of Nivian consolidation in FY27 → delivered Q1-FY27 (= BEAT)
Partly delivered
- Guided 50% Export growth for FY27 → Q1-FY27 results show progress but full year pending (= PARTIAL)
Investor Presentation filed with NSE, NSE: BETA. Summary written with AI assistance from the document.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,981.10
- Market cap
- ₹2,196 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 48.2×Sector 47.4×
- Promoter holding
- 59.10%-5.53% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Business Update
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Annual General Meeting
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Management Change
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Board Meeting Outcome
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Board Meeting Date
Beta Drugs Limited has scheduled a board meeting for September 3, 2026. The agenda includes fixing the 21st AGM details and approving the Director’s Report.
Beta Drugs Capital Structure Change
Beta Drugs Limited approved the allotment of 35,383 bonus equity shares. These shares were issued to holders of Compulsorily Convertible Debentures following their conversion.